MapLight Therapeutics (MPLT) CSO sells 22,082 shares under 10b5-1 plan

Rhea-AI Filing Summary

Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics, Inc., reported selling 22,082 shares of Voting Common Stock on August 3, 2026 at a weighted average price of $12.54 per share, in transactions ranging from $12.12 to $12.99, pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025. Following this sale, Woodruff directly holds 202,380 shares of the company’s common stock.

Insider Trade Summary 10b5-1

Net Seller: 22,082 shares

Net Sell 1 txn

Insider Lillie James Woodruff

Role Chief Scientific Officer

Sold 22,082 shs ($277K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock F1, F2	22,082	$12.54	$277K

Holdings After Transaction: Voting Common Stock — 202,380 shares (Direct)

Footnotes (2)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 22,082 shares Weighted average sale price: $12.54 per share Sale price range: $12.12 to $12.99 per share +2 more

5 metrics

Shares sold 22,082 shares Voting Common Stock sold on August 3, 2026

Weighted average sale price $12.54 per share Average price for the 22,082 shares sold

Sale price range $12.12 to $12.99 per share Range of prices for individual sale transactions

Shares owned after sale 202,380 shares Direct holdings of CSO following the transaction

10b5-1 plan adoption date December 29, 2025 Date the CSO adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, Voting Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Voting Common Stock financial

"security_title: "Voting Common Stock""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 08:40 PM Accepted by SEC EDGAR 08/04/2026 - 08:39 PM Learn about SEC filing dates

FAQ

What insider transaction did MapLight Therapeutics (MPLT) disclose for its Chief Scientific Officer?

MapLight Therapeutics’ Chief Scientific Officer, Lillie James Woodruff, reported selling 22,082 shares of Voting Common Stock on August 3, 2026. The sale was under a Rule 10b5-1 trading plan, and she now directly holds 202,380 shares.

At what price did the MapLight Therapeutics (MPLT) CSO sell her shares?

The CSO’s sale had a weighted average price of $12.54 per share. According to the disclosure, individual trades occurred at prices ranging from $12.12 to $12.99 per share, all part of the same reported transaction.

How many MapLight Therapeutics (MPLT) shares does the CSO still own after this sale?

After the reported sale, Chief Scientific Officer Lillie James Woodruff directly owns 202,380 shares of MapLight Therapeutics Voting Common Stock. This figure reflects her holdings immediately following the August 3, 2026 transaction.

Was the MapLight Therapeutics (MPLT) insider sale made under a Rule 10b5-1 plan?

Yes. The sale was executed under a Rule 10b5-1 trading plan adopted by Lillie James Woodruff on December 29, 2025. Such plans pre-arrange trades according to set instructions, as noted in the disclosure’s footnote.

How many MapLight Therapeutics (MPLT) shares were sold in this Form 4 transaction?

The Form 4 reports that 22,082 shares of MapLight Therapeutics Voting Common Stock were sold. These shares were disposed of in multiple trades on August 3, 2026 within a disclosed price range between $12.12 and $12.99 per share.

What does the weighted average price mean in MapLight Therapeutics (MPLT)’s insider sale?

The filing lists a weighted average price of $12.54 because the 22,082 shares were sold in multiple trades between $12.12 and $12.99. The insider notes they can provide detailed breakdowns of shares sold at each individual price upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lillie James Woodruff

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	08/03/2026		S(1)		22,082	D	$12.54(2)	202,380	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)